A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.
Tsimikas S.
J Am Coll Cardiol. 2017 Feb 14;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042.
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.
Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, Michael LF, Ruotolo G, Gribble G, Navar AM, Nicholls SJ.
JAMA. 2023 Dec 5;330(21):2075-2083. doi: 10.1001/jama.2023.21835.
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.
Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease.
Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14.
Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels.
Eraikhuemen N, Lazaridis D, Dutton MT.
Am J Cardiovasc Drugs. 2021 May;21(3):255-265. doi: 10.1007/s40256-020-00437-7.
Lipoprotein(a) and cardiovascular disease.
Boffa MB, Koschinsky ML.
Biochem J. 2024 Oct 2;481(19):1277-1296. doi: 10.1042/BCJ20240037.
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.
Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, Wilson RJ, Boyce M, Ray KK, Cho L, Watts GF, Koren M, Turner T, Stroes ES, Melgaard C, Campion GV.
JAMA. 2022 May 3;327(17):1679-1687. doi: 10.1001/jama.2022.5050.
Lipoprotein(a), platelet function and cardiovascular disease.
Bhatia HS, Becker RC, Leibundgut G, Patel M, Lacaze P, Tonkin A, Narula J, Tsimikas S.
Nat Rev Cardiol. 2024 May;21(5):299-311. doi: 10.1038/s41569-023-00947-2. Epub 2023 Nov 8.
Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG.
JAMA. 2009 Jun 10;301(22):2331-9. doi: 10.1001/jama.2009.801.
Dietary natural products as emerging lipoprotein(a)-lowering agents.
Momtazi-Borojeni AA, Katsiki N, Pirro M, Banach M, Rasadi KA, Sahebkar A.
J Cell Physiol. 2019 Aug;234(8):12581-12594. doi: 10.1002/jcp.28134. Epub 2019 Jan 13.
Lipoprotein(a) as a cardiovascular risk factor: current status.
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel.
Eur Heart J. 2010 Dec;31(23):2844-53. doi: 10.1093/eurheartj/ehq386. Epub 2010 Oct 21.
